Dianthus Therapeutics, Inc.
DNTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001690585
In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.40B in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Dianthus Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 39
- +9 vs. Q3 2023
- Shares held
- 10.3M
- +218.5K (+2.2%) vs. Q3 2023
- Total value
- $106.5M
- −$29.8M (−21.9%) vs. Q3 2023
- New holders
- 10
- 10 more added
- Sold out
- 1
- 7 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DNTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 269 | $6.40B |
| Q1 2026 | 241 | $5.18B |
| Q4 2025 | 166 | $2.02B |
| Q3 2025 | 140 | $1.84B |
| Q2 2025 | 103 | $728.6M |
| Q1 2025 | 99 | $685.5M |
| Q4 2024 | 96 | $765.7M |
| Q3 2024 | 91 | $858.7M |
| Q2 2024 | 74 | $768.8M |
| Q1 2024 | 76 | $782.3M |
| Q4 2023 | 39 | $106.5M |
| Q3 2023 | 30 | $136.3M |
| Q2 2023 | 46 | $22.0M |
| Q1 2023 | 52 | $23.6M |
| Q4 2022 | 54 | $11.1M |
| Q3 2022 | 72 | $65.8M |
| Q2 2022 | 75 | $54.6M |
| Q1 2022 | 93 | $138.9M |
| Q4 2021 | 94 | $211.4M |
| Q3 2021 | 93 | $276.0M |
| Q2 2021 | 97 | $366.3M |
| Q1 2021 | 90 | $418.4M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Dianthus Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Institutional & Family Asset Management, LLC | 3 | $31 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 3 | $31 | 0.00% | +3 | New |
| JPMorgan Chase & Co | 41 | $426 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 55 | $572 | 0.00% | −100−64.5% | Reduced |
| Wells Fargo & Company | 74 | $769 | 0.00% | +24+48.0% | Added |
| UBS Group AG | 380 | $3.95K | 0.00% | +61+19.1% | Added |
| Royal Bank of Canada | 335 | $4.00K | 0.00% | −4−1.2% | Reduced |
| ADAR1 Capital Management, LLC | 481 | $5.00K | 0.00% | +481 | New |
| Qube Research & Technologies Ltd | 802 | $8.34K | 0.00% | +799+26,633.3% | Added |
| Tower Research Capital LLC (TRC) | 2,430 | $25.3K | 0.00% | +2,430 | New |
| Bank of America Corp | 4,129 | $42.9K | 0.00% | +4,007+3,284.4% | Added |
| RBF Capital, LLC | 10,784 | $112.2K | 0.01% | −4,892−31.2% | Reduced |
| Jefferies Financial Group Inc. | 13,200 | $137.3K | 0.00% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 14,736 | $153.3K | 0.00% | +14,736 | New |
| Bessemer Group Inc | 14,829 | $154.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 15,301 | $159.1K | 0.00% | +15,301 | New |
| Jane Street Group, LLC | 15,678 | $163.1K | 0.00% | +15,678 | New |
| Citigroup Inc | 17,407 | $181.0K | 0.00% | +13,539+350.0% | Added |
| Acadian Asset Management LLC | 17,888 | $184.0K | 0.00% | −4,411−19.8% | Reduced |
| ArrowMark Colorado Holdings LLC | 20,788 | $216.2K | 0.00% | 00.0% | Unchanged |
| Laurion Capital Management LP | 26,267 | $273.2K | 0.01% | −10,126−27.8% | Reduced |
| Susquehanna International Group, LLP | 28,679 | $298.3K | 0.00% | +28,679 | New |
| BlackRock Inc. | 32,306 | $336.0K | 0.00% | +155+0.5% | Added |
| Millennium Management LLC | 33,964 | $353.2K | 0.00% | +33,964 | New |
| Fred Alger Management, LLC | 40,841 | $424.7K | 0.00% | +40,841 | New |
| Geode Capital Management, LLC | 45,179 | $469.9K | 0.00% | +18,838+71.5% | Added |
| Renaissance Technologies LLC | 49,306 | $513.0K | 0.00% | +14,090+40.0% | Added |
| Vestal Point Capital, LP | 135,000 | $1.40M | 0.15% | +135,000 | New |
| Vanguard Group Inc | 153,646 | $1.60M | 0.00% | +26,769+21.1% | Added |
| Alphabet Inc. | 208,697 | $2.17M | 0.10% | 00.0% | Unchanged |
| Atlas Venture Life Science Advisors, LLC | 236,979 | $2.46M | 0.29% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 328,433 | $3.42M | 0.34% | −8,429−2.5% | Reduced |
| Tang Capital Management LLC | 504,242 | $5.24M | 0.48% | −87,394−14.8% | Reduced |
| Octagon Capital Advisors LP | 554,000 | $5.76M | 0.92% | +74,000+15.4% | Added |
| VR Adviser, LLC | 927,706 | $9.65M | 0.66% | 00.0% | Unchanged |
| Avidity Partners Management LP | 1,217,554 | $12.7M | 0.48% | 00.0% | Unchanged |
| 5AM Venture Management, LLC | 1,472,264 | $15.3M | 4.06% | 00.0% | Unchanged |
| Fairmount Funds Management LLC | 1,928,503 | $20.1M | 2.12% | 00.0% | Unchanged |
| FMR LLC | 2,218,212 | $22.6M | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −105,561−100.0% | Sold out |